Ovarian Cancer Research Alliance ’s Post

Most Common Cancers in the US 1) Breast Cancer 2) Lung Cancer 3) Prostate Cancer --------- --------- Find Others at - https://rb.gy/sjiql9 #worldcancerday #worldcancerawarenessday

🔬 New Article Published on Medium! 🔬 I am pleased to share my latest article on Medium "Tri-Specific Nano-Antibodies in Cancer Immunotherapy" This article delves into the groundbreaking research by Ye et al. on a novel immunotherapy approach using tri-specific nano-antibodies (TriNAbs) to boost the effectiveness of NK and CD8+ T cells in combating cancer. Key highlights: - Development and creation of TriNAbs - TriNAbs' success in targeting murine melanoma and colon cancer - Application of Hu TriNAbs against colon cancer tumor organoids #CancerResearch #Immunotherapy #Biotechnology #HealthcareInnovation #MediumArticle

This extraordinary video vividly displays the confrontation between T-cells and cancer cells. A sensor within the cancer cell activates and emits light upon contact, offering real-time insights to significantly improve treatment methodologies. The cancer cell in this case is equipped with a sensor that emits luminescence upon interaction with a T-cell. The referenced video effectively demonstrates the process post-immunotherapy, capturing the engagement between a Cytotoxic T-Lymphocyte (CTL) and aggressive cancer cell. The application of cell therapy, particularly through the utilization of specialized anti-cancer cells known as CAR-T cells, has transitioned from a conceptual possibility to a tangible therapeutic option in contemporary cancer treatment. https://lnkd.in/gj2jib33 Credit for this video goes to: Jeroen Slaats and biotech.symposium.

Exciting news from UCL researchers! A groundbreaking immunotherapy using gamma-delta T cells shows promise in treating osteosarcoma and bone metastases. This innovative approach, OPS-gdT, outperformed conventional therapies in controlling tumor growth in preclinical trials. Learn more about this game-changing development in cancer treatment. #Immunotherapy #CancerResearch #Innovation #UCLResearch

🌐 Diagnostics, Volume 13, Issue 2 (January-2 2023) 🔬 THSD7A Positivity Is Associated with High Expression of FAK in Prostate Cancer 🔍 Several studies indicate that THSD7A might play a role at least in the prognosis of different tumor types. FAK, a key player in prostate cancer progression, is being explored as a therapeutic target, particularly in advanced stages. 💡 This research investigates whether THSD7A expression impacts the expression of FAK in its unphosphorylated form. With evidence pointing to THSD7A’s involvement in FAK-dependent pathways, it opens the discussion of THSD7A as a potential therapeutic target in prostate cancer. 📖 Discover more: https://lnkd.in/d9kvcMH3 #THSD7A #FAK #ProstateCancer #Diagnostics

Our chapter, Theranostic Nanoparticles: Revolutionizing Cancer Diagnosis and Treatment, is now available in Nanoparticles in Cancer Therapy published by CRC Press! 🧬✨ Co-authored with Gagandeep Singh, Himanshu, and Neelam Thakur, this work delves into the dual potential of theranostic nanoparticles to both diagnose and treat cancer with precision. 🎯 🔍 Key insights: Innovative nanoparticles for real-time cancer imaging Targeted delivery of therapeutics Personalized approaches for cancer treatment Discover the future of cancer care here: https://lnkd.in/gmBdy2ac #Theranostics #Nanotechnology #CancerDiagnosis #CancerTherapy #OncologyInnovation #CancerResearch #ScientificPublication #Healthcare #TargetedTherapy #FutureOfMedicine

Nanoparticle-based drug delivery in the fight against cancer This animation describes the latest research developments in nanoparticle-based cancer therapies. It explores how the technology can be used to specifically target cancer cells over healthy cells and how scientists can exploit the natural processes of cells to deliver the drug inside the cell where it is needed for its cancer-killing effect. #Nanoparticle #Drugdelivery #cancer

Circulating tumor DNA (ctDNA) can detect primary resistance to immunotherapy in patients with lung cancer. In the first stage of this phase 2 trial, we evaluated 50 patients with advanced non-small cell lung cancer who received standard of care pembrolizumab to determine ctDNA response and its concordance with imaging. The primary endpoint was achieved and showed an impressive 82% sensitivity and 75% specificity in predicting radiologic response. These findings are guiding the ctDNA driven second stage of this trial where patients at risk of early progression are randomized to treatment intensification. Check out this one-page graphical summary of the manuscript.

💫 #ESMO24 Day 4 Roundup 💫 🌟 Novel Antibody-Drug Conjugate Puxitatug Samrotecan May Demonstrate Manageable Safety Profile and Preliminary Efficacy in First-in-Human Trial 👉 Phase II expansion cohorts are ongoing in ovarian cancer, breast cancer, endometrial cancer, and biliary tract cancer. 🔗 https://buff.ly/3TyKnky #OncEd #OncoAlert

🔊 EXCITING NEWS! 🔊 According to the Prostate Cancer Foundation just a few hours ago, researchers have revealed promising new treatment for advanced metastatic castration-resistant prostate cancer (abbreviated mCRPC)! This news came in light of positive results achieved from a clinical trial using CAR T-cell therapy. To read more about this revolutionary treatment: https://lnkd.in/dmsuvapx